A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial.
Kalani L RaphaelTamara IsakovaJoachim H IxDominic S RajMyles WolfLinda F FriedJennifer J GassmanCynthia KendrickBrett LariveMichael F FlessnerSusan R MendleyThomas H HostetterGeoffrey A BlockPing LiJohn P MiddletonStuart M SpragueDonald E WessonAlfred K CheungPublished in: Journal of the American Society of Nephrology : JASN (2019)
Both NaHCO3 doses were well tolerated over 28 weeks with no significant difference in adverse events or hospitalization compared with placebo. The higher dose lowered urinary ammonium excretion and increased serum bicarbonate more than the lower dose but was associated with a greater increase in ACR. The higher 0.8 meq/kg of lean body wt per day dose of NaHCO3 may be a reasonable choice for future trials.